Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

Siqing Fu, Bryan T. Hennessy, Chaan S. Ng, Zhenlin Ju, Kevin R. Coombes, Judith K. Wolf, Anil K. Sood, Charles F. Levenback, Robert L. Coleman, John J. Kavanagh, David M. Gershenson, Maurie Markman, Kristine Dice, Adrienne Howard, Jane Li, Yang Li, Katherine Stemke-Hale, Mary Dyer, Edward Atkinson, Ed JacksonVikas Kundra, Razelle Kurzrock, Robert C. Bast, Gordon B. Mills

    Research output: Contribution to journalArticle

    50 Scopus citations

    Abstract

    Objectives: On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer. Methods: Patients with pathologically confirmed high-grade epithelial ovarian cancer (taxane resistant, n = 10; taxane refractory, n = 11) were enrolled. Peripheral blood samples and tumor biopsies were obtained and 18F-FDG-PET and DCE-MRI scans were performed for pharmacodynamic and imaging studies. Results: Patients received a total of 42 treatment cycles. No dose-limiting toxicity was observed. The median progression-free survival and overall survival were 1.9 months and 4.5 months, respectively. One patient with a PTEN mutation achieved a partial remission (PR) for 7.5 months, and another patient with a PIK3CA mutation had stable disease (SD) for 4 months. Two other patients without apparent PI3K pathway aberrations achieved SD. Two patients with KRAS mutations demonstrated rapid progression. Decreased phosphorylated S6 correlated with 18F-FDG-PET responses. Conclusions: Patients tolerated perifosine 150 mg PO daily plus docetaxel at 75 mg/m 2 every 4 weeks. Further clinical evaluation of effects of perifosine with docetaxel on biological markers and efficacy in patients with ovarian cancer with defined PI3K pathway mutational status is warranted.

    Original languageEnglish (US)
    Pages (from-to)47-53
    Number of pages7
    JournalGynecologic oncology
    Volume126
    Issue number1
    DOIs
    StatePublished - Jul 1 2012

      Fingerprint

    Keywords

    • AKT
    • Docetaxel
    • Epithelial ovarian cancer
    • Perfosine
    • Platinum resistance
    • Taxane resistance

    ASJC Scopus subject areas

    • Oncology
    • Obstetrics and Gynecology

    Cite this

    Fu, S., Hennessy, B. T., Ng, C. S., Ju, Z., Coombes, K. R., Wolf, J. K., Sood, A. K., Levenback, C. F., Coleman, R. L., Kavanagh, J. J., Gershenson, D. M., Markman, M., Dice, K., Howard, A., Li, J., Li, Y., Stemke-Hale, K., Dyer, M., Atkinson, E., ... Mills, G. B. (2012). Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic oncology, 126(1), 47-53. https://doi.org/10.1016/j.ygyno.2012.04.006